Uses of Encorate 500mg

This is an automatically translated article.

1. What is Encorate 500mg?

Encorate 500 has the ingredients in each tablet of sodium valproate and valproic acid, equivalent to 500mg of sodium valproate and a system of excipients including: HPMC K100M, HPMC K15M, Corn Starch, Colloidal Silicon Dioxide, Talc Powder , Magnesium Stearate, Titanium Dioxide, Eudragit E100, Sunset Yellow lake, PEG 6000, Sodium Lauryl Sulfate.
Valproic acid or sodium valproate is an antiepileptic drug through an inhibitor of the neurotransmitter gamma - aminobutyric acid (GABA), increasing GABA concentrations by inhibiting GABA metabolism or increasing postsynaptic GABA activity because Valproat can therefore be used in many types of seizures.

2. Uses of Encorate 500

Encorate 500 is indicated for use in all types of seizures: absence of consciousness, chorea, tonic-clonic seizures, atony, complex as well as simple or complex seizures, secondary generalized epilepsy and characteristic syndromes; Encorate 500 is used in manic episodes (manic mania) due to bipolar disorder (also known as manic-depressive disorder); Encorate 500 is used to prevent migraine headaches.

3. Dosage of Encorate 500

Dosage of Encorate 500 in epilepsy:
Adults: Initially 600mg/day in 2 divided doses, preferably after meals, increase to 200mg/day, gradually increasing every 3 days until reaching optimal seizure control. Encorate 500 tablets need to be swallowed whole and not chewed or crushed, the maximum recommended dose with the main active ingredient of Encorate 500 is 1 - 2g; Children over 20kg: Initial dose is 400mg/day in 2 divided doses, gradually increase the dose until the disease is controlled (usually about 20-30mg/kg/day), the maximum is 35mg/day. kg/day in this subject; Children under 20 kg: Encorate 500 is not suitable for children under 20 kg. Treatment of Encorate 500 in manic episode (manic mania) due to bipolar disorder:
Start the drug with 750mg/day, divided into 2-3 times, increase the dose gradually depending on the response to treatment, the usual dose Usually 1-2g/day. Prevention of migraine:
The initial dose is 300 mg/2 times/day, increased if necessary to a dose of 1-2 g/day, divided into 2 times. Dosage of Encorate 500 in Renal Impairment:
The lowest effective dose should be used because high concentrations of free Encorate 500 may lead to decreased serum albumin and poor urinary excretion of substances. free transformation. Use of Encorate 500 in the elderly:
The pharmacokinetics of sodium valproate are altered in the elderly, but clinical limitations are still limited, so the dose of Encorate 500 should be determined based on clinical control. seizure control. Adolescent girls, women of reproductive age and pregnant women:
Encorate 500 should be initiated and closely monitored by a specialist in epilepsy or bipolar disorder. In extreme cases, use this drug only when other treatments are ineffective or the patient is intolerant. The benefit-risk balance of Encorate 500 should be balanced at each routine patient visit, preferably Encorate 500 should be prescribed as monotherapy, the lowest effective dose, the daily dose should be divided into at least 2 single doses. Encorate 500 overdose symptoms:
Nausea, vomiting and dizziness that occur when an overdose of Encorate 500 is not serious; When the concentration of Encorate 500 in the blood plasma is 10 - 20 times the maximum therapeutic concentration, it causes severe central nervous system depression, respiratory failure, seizures, which can lead to death. Treatment of drug overdose Encorate 500:
Induce vomiting, gastric lavage; Support ventilation; Seizures: use Diazepam; Hemodialysis and blood transfusion are effective; Intravenous naloxone is effective in some cases; Combined oral activated charcoal.

4. Contraindications of Encorate 500

Acute hepatitis; Chronic hepatitis ; Personal or family history of severe hepatitis; Hypersensitivity to sodium valproate; Porphyrin metabolism disorders; Prophylaxis of acute migraine attacks in pregnant women and women of childbearing age who do not use contraceptive methods during treatment with Valproat.

5. Note when using Encorate 500

Monitor liver function before treatment with Encorate 500 and during the first 6 months; Patients with renal failure, systemic lupus erythematosus, avoid abrupt discontinuation of Encorate 500; Doses higher than 45 mg/kg/day should be closely monitored. Warning:
Valproic acid inhibits platelet aggregation, there is a risk of prolonging bleeding time so for patients undergoing surgery should evaluate the possibility of bleeding complications; Patients who are taking Valproat for a long time who develop spontaneous bruising and bleeding should stop taking Encorate 500 immediately and may resume treatment after blood tests return to normal; Valproate can lead to drug-induced pancreatitis within 6 months of treatment with acute abdominal pain. If drug-induced pancreatitis occurs, Encorate 500 should be discontinued and another antiepileptic drug substituted. Liver dysfunction, liver failure caused by Encorate 500 is common in epileptic children with degenerative diseases or other congenital metabolic diseases, organic encephalopathy and mental retardation; Diabetics may give false positive results in urine ketone testing while taking Encorate 500. Encorate 500 may cause drowsiness, which is worse when used with other antiepileptic drugs or with benzodiazepines such as lorazepam, affecting the ability to drive or operate machines. Encorate 500 may cause weight gain in some people; Encorate 500 should not be used in girls, female adolescents, women of childbearing age, and pregnant women because valproate has a high potential for teratogenicity and developmental disorders in children exposed to valproate during the mother's time. pregnant; Women of childbearing age are required to use contraception during treatment with Encorate 500.

6. Side effects of Encorate 500

Central nervous system: causing drowsiness, dizziness, convulsions, coma or agitation, aggression; On the liver: Liver dysfunction, liver failure can be fatal (risk is highest in children under 3 years of age with mental retardation, organic encephalopathy, or metabolic disorder); Gastrointestinal: Increased appetite, weight gain, sadness; Metabolism: Temporarily elevated serum ammonium, if combined with decreased consciousness, vomiting and ataxia, Encorate 500 should be discontinued immediately; Pancreas: Acute pancreatitis; Hematopoietic system: prolongation of bleeding time (increased INR), thrombocytopenia, pancytopenia, hypoplasia of red blood cells; On the skin: Vasculitis, alopecia, erythema, excessive hair growth, acne; Other: Dementia, Steven-Johnson syndrome, amenorrhea, gynecomastia, Fanconi syndrome, toxic epidermal necrolysis.

7. Interactions of Encorate 500 with other drugs

Lamotrigine: Encorate 500 reduces the metabolism of lamotrigine; Phenytoin: Encorate 500 may increase the risk of liver side effects when taken together; Phenobarbital: Phenobarbital serum concentrations may be increased when co-administered with Encorate 500 leading to excessive somnolence. Carbamazepine: Reduces plasma concentrations of Encorate 500 by increasing the metabolism of Valproate; Cimetidine : Prolongs the half-life of Encorate 500 ; Encorate 500 enhances the effect of CNS depressants (including alcohol); Warfarin, Aspirin: be careful when using Encorate 500 with these drugs; Cholestyramine: May reduce the absorption of Encorate 500 from the intestine, should be taken at least 3 hours apart; Olanzapine: There may be an increased risk of leukopenia if olanzapine is co-administered with Encorate 500.

Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.